CA2558659A1 - Genetically engineered canary poxvirus-based vaccine strain - Google Patents
Genetically engineered canary poxvirus-based vaccine strain Download PDFInfo
- Publication number
- CA2558659A1 CA2558659A1 CA002558659A CA2558659A CA2558659A1 CA 2558659 A1 CA2558659 A1 CA 2558659A1 CA 002558659 A CA002558659 A CA 002558659A CA 2558659 A CA2558659 A CA 2558659A CA 2558659 A1 CA2558659 A1 CA 2558659A1
- Authority
- CA
- Canada
- Prior art keywords
- virus
- inactivated
- recombinant
- genetic functions
- poxvirus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229960005486 vaccine Drugs 0.000 title abstract 4
- 241000178270 Canarypox virus Species 0.000 title abstract 2
- 241000700605 Viruses Species 0.000 abstract 4
- 230000002068 genetic effect Effects 0.000 abstract 4
- 108700026244 Open Reading Frames Proteins 0.000 abstract 2
- 230000007923 virulence factor Effects 0.000 abstract 2
- 239000000304 virulence factor Substances 0.000 abstract 2
- 230000002238 attenuated effect Effects 0.000 abstract 1
- 230000002779 inactivation Effects 0.000 abstract 1
- 230000001018 virulence Effects 0.000 abstract 1
Landscapes
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
What is described is a modified vector, such as a recombinant poxvirus, particularly recombinant canary poxvirus, having enhanced safety. The modified recombinant virus has nonessential virus-encoded genetic functions inactivated therein so that virus has attenuated virulence.
In one embodiment, the genetic functions are inactivated by deleting an open reading frame encoding a virulence factor.
In another embodiment, the genetic functions are inactivated by insertional inactivation of an open reading frame encoding a virulence factor. What is also described is a vaccine containing the modified recombinant virus having nonessential virus-encoded genetic functions inactivated therein so that the vaccine has an increased level of safety compared to known recombinant virus vaccines.
In one embodiment, the genetic functions are inactivated by deleting an open reading frame encoding a virulence factor.
In another embodiment, the genetic functions are inactivated by insertional inactivation of an open reading frame encoding a virulence factor. What is also described is a vaccine containing the modified recombinant virus having nonessential virus-encoded genetic functions inactivated therein so that the vaccine has an increased level of safety compared to known recombinant virus vaccines.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA2621088A CA2621088C (en) | 1991-03-07 | 1992-03-09 | Genetically engineered fowlpox-based vaccine strain |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US66605691A | 1991-03-07 | 1991-03-07 | |
| US666,056 | 1991-03-07 | ||
| US71396791A | 1991-06-11 | 1991-06-11 | |
| US713,967 | 1991-06-11 | ||
| US84795192A | 1992-03-06 | 1992-03-06 | |
| US847,951 | 1992-03-06 | ||
| CA002105277A CA2105277C (en) | 1991-03-07 | 1992-03-09 | Genetically engineered vaccine strain |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002105277A Division CA2105277C (en) | 1991-03-07 | 1992-03-09 | Genetically engineered vaccine strain |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2621088A Division CA2621088C (en) | 1991-03-07 | 1992-03-09 | Genetically engineered fowlpox-based vaccine strain |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2558659A1 true CA2558659A1 (en) | 1992-09-17 |
| CA2558659C CA2558659C (en) | 2008-06-03 |
Family
ID=37310264
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002558659A Expired - Lifetime CA2558659C (en) | 1991-03-07 | 1992-03-09 | Genetically engineered canary poxvirus-based vaccine strain |
Country Status (1)
| Country | Link |
|---|---|
| CA (1) | CA2558659C (en) |
-
1992
- 1992-03-09 CA CA002558659A patent/CA2558659C/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| CA2558659C (en) | 2008-06-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU1001297A (en) | ALVAC canarypox virus recombinants comprising heterologous inserts | |
| OA09777A (en) | "Viral defective vaccine produced by transcomplementing cell line" | |
| NO933260L (en) | RECOMBINANT VIRUS VECTORS CODING FOR HUMAN PAPILLOMAVIRUS PROTEINS | |
| CA2031164A1 (en) | Recombinant herpesvirus of turkeys and live vector vaccines derived thereof | |
| AU6564596A (en) | Recombinant Attenuated TROVAC Fowlpox Vectors Containing Heterologous DNA Segments Encoding Lentiviral Gene Products | |
| EP0261940A3 (en) | Pseudorabies vaccines and dna vectors for recombination with pox viruses | |
| CA2105277A1 (en) | Genetically engineered vaccine strain | |
| ATE147782T1 (en) | PRIMATE LENTIVIRUS VACCINES | |
| WO1994013812A3 (en) | Novel entomopoxvirus genes, proteins and methods of use thereof | |
| DK0831899T3 (en) | Recombinant smallpox virus calicivirus preparations and applications | |
| DE69333057D1 (en) | Recombinant adenovirus vaccines | |
| CA2558659A1 (en) | Genetically engineered canary poxvirus-based vaccine strain | |
| MXPA94008605A (en) | Viral vector with bovine viral diarrhea virus (bvdv) antigens. | |
| CA2116355A1 (en) | Infectious bovine rhinotracheitis virus mutants and vaccines | |
| DE69920192D1 (en) | RECOMBINANT VIRUS | |
| ATE232238T1 (en) | SYNTHETIC PROMOTERS OF HERPES SIMPLEX VIRUS | |
| WO1992014818A3 (en) | Entomopoxvirus expression system comprising spheroidin or thymidine-kinase sequences | |
| ES2074965A1 (en) | Recombinant infectious bovine rhinotracheitis virus mutant, methods for the production of same, and vaccines containing the same. | |
| Enzo et al. | Genetically engineered vaccine strain | |
| GR3020495T3 (en) | Two-phase system for the production and presentation of foreign antigens in hybrid live vaccines | |
| WO2002078621A3 (en) | Replication-competent recombinant virus and methods of use thereof | |
| RU93056615A (en) | VECTOR, METHOD FOR PRODUCING VECTOR, METHOD FOR PRODUCING MEDICINE, METHOD OF ACTIVATION OF IMMUNITY | |
| CA2621088A1 (en) | Genetically engineered fowlpox-based vaccine strain |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKEX | Expiry |